

Investor Relations Contacts:

Patrick T. Mooney, M.D.
Chairman & CEO
Echo Therapeutics
508-530-0329



Echo Therapeutics to Present Clinical Study Results of Its Symphony Transdermal Continuous Glucose Monitoring System at Annual Diabetes Technology Meeting

Franklin, MA – November 13, 2008 – Echo Therapeutics (OTCBB: ECTE) announced today that it will present clinical trial data this evening at the Eighth Annual Diabetes Technology Meeting in Bethesda, Maryland. The abstract entitled, “Transdermal Glucose Monitoring Enabled by Prelude™ SkinPrep System” will be presented at a poster session from 6:00-8:00 and will highlight the positive results from the most recent clinical trial of Echo’s Symphony™ tCGM System, a non-invasive (needle-free) transdermal continuous glucose monitoring (tCGM) system, in patients with Type 1 and Type 2 diabetes. The Annual Diabetes Technology Meeting is one of the largest gatherings of technology developers and health care professionals focused on delivering leading-edge, cost-effective technologies to help people with diabetes.

The Symphony™ tCGM System measures the continuous flow of glucose through the skin, which is made permeable with Echo’s Prelude™ SkinPrep System, a leading-edge skin permeation device. Information about the meeting can be found on the Diabetes Technology Society website at: <http://www.diabetestechology.org/index.html>

“We are excited to present these positive clinical trial results in a peer-reviewed setting as we continue to build awareness of our Symphony tCGM System. These clinical results represent substantial progress in our Symphony development program,” stated Patrick T. Mooney, M.D., Echo’s Chairman and CEO. “The frequent reference blood measurements in this study with a YSI laboratory analyzer enabled us to evaluate Symphony’s performance with a high level of confidence. We believe Symphony’s safety and accuracy data from this study are comparable to all FDA-approved invasive (needle-based) CGM devices. We look forward to continued progress in our late-stage Symphony development programs.”

About Echo Therapeutics

Echo Therapeutics is focused on transdermal medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, together with a wide range of novel transdermal reformulations of FDA-approved products.

Forward Looking Statements

Echo's Symphony tCGM System has not yet been approved for sale. The regulatory approval process for the Symphony tCGM System involves, among other things, successfully completing clinical trials and obtaining a premarket approval, or PMA, from the FDA and corresponding foreign regulatory authorities. The PMA process requires Echo to prove the safety and efficacy of the Symphony tCGM System to the FDA's satisfaction. This process can be expensive and uncertain, and there is no guarantee that Echo will be able to submit a PMA for the Symphony tCGM System or that such system will be approved by the FDA in any specific timeframe, or at all. In addition, clinical testing of Echo's products and eventual commercialization of its products are subject to all of the risks and uncertainties set forth in its periodic reports filed with the U.S. Securities and Exchange Commission.



10 Forge Parkway
Franklin, MA 02038, USA
Tel: 1+ 877-476-6878
Fax: 1+ 508-553-8760
www.echotx.com

© 2002 - 2008 Echo Therapeutics, Inc. All rights reserved worldwide.